NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors

被引:139
|
作者
Fan, ZS
Yu, P
Wang, Y
Wang, YG
Fu, ML
Liu, WH
Sun, YL
Fu, YX
机构
[1] Chinese Acad Sci, Natl Lab Biomacromol, Beijing 100101, Peoples R China
[2] Chinese Acad Sci, Ctr Infect & Immun, Inst Biophys, Beijing 100101, Peoples R China
[3] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
关键词
D O I
10.1182/blood-2005-08-3485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural killer (NK) cells are generally reported as innate effector cells for killing virally infected and transformed cells. It is unclear how NK cells evoke adaptive immunity to eradicate tumors. We now demonstrate that the TNF superfamily member, LIGHT, known as TNFSF14 and a T-cell costimulatory molecule, is a critical ligand for the activation of NK cells. Herpesvirus entry mediator (HVEM) is expressed on NK cells, and its engagement with LIGHT mediates NK-cell activation. dent manner. Both NK and CD8(+) cells are essential but not sufficient for the rejection of tumors because mice lacking either population fail to reject the tumor. Interestingly, activated NK cells do not kill tumors directly but can facilitate the priming of tumor-specific CD8(+) T cells in an IFN-gamma-dependent manner. Conversely, intratumor depletion of either NK cells or IFN-gamma during tumor progression disrupts CD8(+) cell-mediated tumor rejection, suggesting that the tumor is the essential site for the crosstalk between NK and CD8(+) cells. Furthermore, IFNG-deficient NK cells fail to effectively activate CD8(+) T cells, suggesting IFN-gamma plays an important role in NK-mediated activation of cytotoxic T lymphocytes (CTLs). Our findings establish a direct role for LIGHT in NK activation/expansion and a critical helper role of activated NK cells in priming CD8(+) T cells and breaking T-cell tolerance at the tumor site.
引用
收藏
页码:1342 / 1351
页数:10
相关论文
共 50 条
  • [1] Tracking tumor-specific CD8+ T cell responses
    Burke, Kelly P.
    Markson, Samuel C.
    Sharpe, Arlene H.
    [J]. TRENDS IN IMMUNOLOGY, 2023, 44 (05) : 326 - 328
  • [2] CD8+ T-cell immunity to cytomegalovirus
    Moss, P
    Khan, N
    [J]. HUMAN IMMUNOLOGY, 2004, 65 (05) : 456 - 464
  • [3] Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer
    Karanikas, Vaios
    Zamanakou, Maria
    Soukou, Faye
    Kerenidi, Theodora
    Gourgoulianis, Konstantinos I.
    Germenis, Anastasios E.
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2010, 88 (05): : 575 - 585
  • [4] Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment
    Bathe, OF
    Dalyot-Herman, N
    Malek, TR
    [J]. BMC CANCER, 2003, 3 (1)
  • [5] Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment
    Oliver F Bathe
    Nava Dalyot-Herman
    Thomas R Malek
    [J]. BMC Cancer, 3
  • [6] Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
    Gupta, Anurag
    Probst, Hans Christian
    Van Vuong
    Landshammer, Alexandro
    Muth, Sabine
    Yagita, Hideo
    Schwendener, Reto
    Pruschy, Martin
    Knuth, Alexander
    van den Broek, Maries
    [J]. JOURNAL OF IMMUNOLOGY, 2012, 189 (02): : 558 - 566
  • [7] USE OF A SKIN-TEST ASSAY TO DETERMINE TUMOR-SPECIFIC CD8+ T-CELL REACTIVITY
    PUCCETTI, P
    BIANCHI, R
    FIORETTI, MC
    AYROLDI, E
    UYTTENHOVE, C
    VANPEL, A
    BOON, T
    GROHMANN, U
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (06) : 1446 - 1452
  • [8] CD8+ T-CELL IMMUNITY TO TOXOPLASA GONDII
    KASPER, LH
    ELY, K
    KHAN, IA
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 80 - 80
  • [9] The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the ceff-surface receptor CRTAM
    Boles, KS
    Barchet, W
    Diacovo, T
    Cella, M
    Colonna, M
    [J]. BLOOD, 2005, 106 (03) : 779 - 786
  • [10] Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+ T-cell immunity
    Brown, Matthew D.
    van der Most, Robbert
    Vivian, Justin B.
    Lake, Richard A.
    Larma, Irma
    Robinson, Bruce W. S.
    Currie, Andrew J.
    [J]. ONCOIMMUNOLOGY, 2012, 1 (07): : 1084 - 1094